Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sulphasalazine in ankylosing spondylitis.

N Feltelius, R Hällgren

    Annals of the Rheumatic Diseases
    |May 1, 1986
    PubMed
    Summary

    Sulfasalazine shows promise for treating ankylosing spondylitis, a condition lacking effective remission-inducing drugs. This study found it reduced inflammation and improved symptoms with mild side effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden.

    European journal of clinical pharmacology·2018
    Same author

    The immunogenetics of narcolepsy associated with A(H1N1)pdm09 vaccination (Pandemrix) supports a potent gene-environment interaction.

    Genes and immunity·2017
    Same author

    Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up.

    Journal of internal medicine·2016
    Same author

    Response to letter from Lars Andersson.

    Journal of internal medicine·2016
    Same author

    A coordinated cross-disciplinary research initiative to address an increased incidence of narcolepsy following the 2009-2010 Pandemrix vaccination programme in Sweden.

    Journal of internal medicine·2015
    Same author

    Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.

    Arthritis & rheumatology (Hoboken, N.J.)·2014

    Area of Science:

    • Rheumatology
    • Pharmacology

    Background:

    • Ankylosing spondylitis lacks effective remission-inducing therapies.
    • Sulfasalazine is increasingly recognized for rheumatoid arthritis treatment.

    Purpose of the Study:

    • To evaluate the efficacy and safety of sulfasalazine in ankylosing spondylitis patients.
    • To compare sulfasalazine with placebo in a double-blind trial.

    Main Methods:

    • A double-blind, placebo-controlled trial involving 37 patients with ankylosing spondylitis.
    • Treatment duration was three months.

    Main Results:

    • Sulfasalazine demonstrated a reduction in inflammatory activity.
    • Clinical variables showed improvement in the sulfasalazine group.
    • Reported side effects were mild.

    Conclusions:

    • Sulfasalazine appears to be a potentially effective and safe treatment option for ankylosing spondylitis.
    • Further research may support sulfasalazine for managing this condition.

    Related Experiment Videos